The Supervisory Board of the PHOENIX group and the Chairman of the Executive Board Oliver Windholz have mutually agreed not to extend the contract which expires on January 31, 2020. Windholz will conclude his work for the PHOENIX group on September 30, 2019.Windholz has been a member of the PHOENIX group Executive Board since February 1, 2011. On February 1, 2014, he took over as Chairman of the Executive Board and was responsible for Sales and Marketing throughout Europe.
"As CEO, Oliver Windholz has played a decisive role in shaping the company over the past five years and driving successfully business development," said Dr. Bernd Scheifele, Chairman of the Supervisory Board of the PHOENIX group. In more than 25 years in management positions at HeidelbergCement, ratiopharm and PHOENIX, Windholz demonstrated a very high level of personal commitment and loyalty to the companies and the Merckle Group. "The shareholders, the Supervisory Board and the colleagues in the Executive Board thank Oliver Windholz for the very trustworthy and successful cooperation and wish him the very best for his private and professional future," said Dr. Scheifele.
Under the leadership of Windholz, the PHOENIX group transformed from a traditional pharmaceutical wholesaler to an integrated healthcare provider active in 27 countries. The PHOENIX group consistently continued its dynamic growth path through organic growth and acquisitions. As part of the digitalization, Windholz more and more focused on end customers. The number of pharmacies increased significantly and PHOENIX is now a market leader in pharmacy retail in Europe. PHOENIX is also getting closer to the end consumer by marketing its own health products under the LIVSANE brand and expanding its e-commerce activities.
Windholz played a leading role in the creation of the PHOENIX Pharmacy Partnership. It acts as an umbrella for the PHOENIX group’s pharmacy cooperation programmes. With more than 13,500 partner pharmacies in 16 countries, the network is the largest of its kind.